IQVIA Reports Third-Quarter 2022 Results Revenue of $3,562 million grew 5.0 percent year-over-year on a reported basis and 10.5 percent at constant currency GAAP Net Income of $283 million grew 8.4 percent year-over-year

Revenue of $3,562 million grew 5.0 percent year-over-year on a reported basis and 10.5 percent at constant currency

GAAP Net Income of $283 million grew 8.4 percent year-over-year

Adjusted EBITDA of $814 million increased 11.8 percent year-over-year

GAAP Diluted Earnings per Share of $1.49 grew 11.2 percent year-over-year

Adjusted Diluted Earnings per Share of $2.48 increased 14.3 percent year-over-year

R&D Solutions quarterly bookings of over $2.5 billion; excluding pass throughs, quarterly bookings at a historic high of over $2.0 billion, representing a services book-to-bill ratio of 1.39x

R&D Solutions contracted backlog of $25.8 billion grew 5.4 percent year-over-year and 9.4 percent excluding the impact of foreign exchange

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--October 26, 2022--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences

industry, today reported financial results for the quarter ended September 30, 2022.

Third-Quarter 2022 Operating Results

Revenue for the third quarter of $3,562 million increased 5.0 percent on a reported basis and 10.5 percent at constant currency, compared to the third quarter of 2021. Technology & Analytics Solutions (TAS) revenue of $1,400

million grew 4.7 percent on a reported basis and 11.6 percent at constant currency. Research & Development Solutions (R&DS) revenue of $1,979 million increased 6.8 percent on a reported basis and 10.7 percent at constant

currency. Excluding the impact of pass throughs, R&DS revenue grew 7.4 percent year-over-year on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $183 million decreased 9.0 percent on a reported basis and

grew 1.0 percent at constant currency.

As of September 30, 2022, R&DS contracted backlog, including reimbursed expenses, was $25.8 billion, growing 5.4 percent year-over-year and 9.4 percent excluding foreign exchange. The company expects approximately $7.1 billion of

this backlog to convert to revenue in the next twelve months. R&D Solutions quarterly bookings exceeded $2.5 billion and excluding pass throughs were at a historic high of over $2.0 billion. The third-quarter book-to-bill ratio was

1.39x excluding reimbursed expenses and 1.27x including reimbursed expenses. For the twelve months ended September 30, 2022, the book-to-bill ratio was 1.35x excluding reimbursed expenses and 1.29x including reimbursed expenses.

"IQVIA had another outstanding quarter of operational and financial performance," said Ari Bousbib, chairman and CEO of IQVIA. "Each of our business segments delivered impressive organic revenue growth at constant currency, we

increased adjusted diluted earnings per share by over 14 percent, and free cash flow generation was very strong. Despite the global macro environment, demand for IQVIA services and offerings continues to be strong across both the

commercial and the clinical portfolios, with R&DS delivering over $2 billion of services bookings for the first time ever."

Third-quarter GAAP Net Income was $283 million, up 8.4 percent year-over-year, and GAAP Diluted Earnings per Share was $1.49, an increase of 11.2 percent year-over-year. Adjusted Net Income was $470 million, up 11.1 percent

year-over-year, and Adjusted Diluted Earnings per Share was $2.48, up 14.3 percent year-over-year. Adjusted EBITDA was $814 million, increasing 11.8 percent year-over-year.

Year-to-Date 2022 Operating Results

Revenue for the first nine months of 2022 was $10,671 million, up 4.2 percent on a reported basis and 8.1 percent at constant currency compared to the first nine months of 2021. TAS revenue was $4,247 million, representing growth of

5.2 percent reported and 10.3 percent at constant currency. R&DS revenue was $5,863 million, up 4.5 percent on a reported basis and 7.1 percent at constant currency. CSMS revenue was $561 million, down 4.6 percent on a reported

basis and up 2.9 percent at constant currency.

GAAP Net Income for the first nine months of 2022 was $864 million, up 33.3 percent year-over-year and GAAP Diluted Earnings per Share was $4.52, up 36.1 percent year-over-year. Adjusted Net Income was $1,413 million for the first

nine months of 2022, increasing 11.8 percent year-over-year, and Adjusted Diluted Earnings per Share was $7.39, up 14.0 percent year-over-year. Adjusted EBITDA for the first nine months of 2022 was $2,426 million, up 10.6 percent

As of September 30, 2022, cash and cash equivalents were $1,274 million and debt was $12,394 million, resulting in net debt of $11,120 million. IQVIA's Net Leverage Ratio was 3.4x trailing twelve-month Adjusted EBITDA. For the third

quarter of 2022, Operating Cash Flow was $863 million and Free Cash Flow was $698 million. For the first nine months of 2022, Operating Cash Flow was $1,700 million and Free Cash Flow was $1,197 million.

During the third quarter of 2022, the company repurchased $150 million of its common stock, bringing year-to-date share repurchase activity to $1,143 million. IQVIA had $1,380 million of share repurchase authorization remaining as

of September 30, 2022.

Full-Year 2022 Guidance

For the full year of 2022, the company continues to expect low-to-mid teens organic revenue growth at constant currency, excluding COVID-related work. To reflect primarily the impact of the strengthening US dollar and to a lesser

extent, minor delays in the timing of certain trial deliveries due to external macro factors, the company is updating its full-year 2022 revenue guidance range assuming foreign exchange currency rates as of October 24, 2022. The company

now expects revenue to be between $14,325 million and $14,425 million, representing growth of 7.4 to 8.2 percent at constant currency, and 3.2 to 4.0 percent on a reported basis. The company is also updating its Adjusted EBITDA guidance

range to be $3,330 million to $3,360 million, representing growth of 10.2 to 11.2 percent. Additionally, the company is raising Adjusted Diluted Earnings per Share by 5 cents at the midpoint. Adjusted Diluted Earnings per Share is

expected to be between $10.10 to $10.20, up 11.8 to 13.0 percent on a reported basis.

Fourth-Quarter 2022 Guidance

For the fourth quarter of 2022, the company expects revenue to be between $3,654 million and $3,754 million, representing growth of 5.5 to 8.2 percent at constant currency and 0.5 to 3.2 percent on a reported basis, with underlying

constant currency organic growth excluding COVID-related work of over 10 percent at the midpoint. The company expects Adjusted EBITDA to be between $904 million and $934 million and Adjusted Diluted Earnings per Share to be between

$2.72 and $2.82, representing growth of 9.2 to 12.8 percent and 6.7 to 10.6 percent on a reported basis, respectively.

All financial guidance assumes foreign currency exchange rates as of October 24, 2022 remain in effect for the forecast period.

Webcast & Conference Call Details

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its third-quarter 2022 results and its fourth-quarter and full-year 2022 guidance. To listen to the event and view the presentation slides via webcast,

join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a

confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information

provided in the confirmation email and will be placed directly into the call.

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through

its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence delivers powerful insights with speed and agility - enabling customers to accelerate the clinical development and

commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 85,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale

that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and

pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behavior and scientific advances, in an effort to advance their path toward

cures. To learn more, visit www.iqvia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

amended, including, without limitation, our fourth-quarter and full-year 2022 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often

contain words such as "expect," "assume," "anticipate," "intend," "plan," "forecast," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words that are intended to identify

forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the

following: business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, international conflicts or other

disruptions outside of our control such as the current situation in Ukraine and Russia; our ability to accurately model or forecast the impact of the spread and/or containment of COVID-19, including any variants, among other sources of

business interruption, on our operations and financial results; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the

market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data

to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners'

security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our

susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and

timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements;

the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic

concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or

may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks

related to changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in

tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to our business, see the "Risk Factors" in our annual

report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in our subsequent periodic and other filings

with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in

our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures

This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS,

and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company's financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company's financial

performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company's results of operations as

determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more

meaningful indicator of the underlying operating performance of the business. For example, the Company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases,

non-compete agreements and trademarks, trade names and other from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired

intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income attributable to IQVIA Holdings

Inc. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP

financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP

measures. Our fourth-quarter and full-year 2022 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with

a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based

compensation and other items not reflective of the company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results.

Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for

the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not

consider such performance measures in isolation from, or as a substitute analysis for, the company's results of operations as determined in accordance with GAAP.